Pyridostigmine bromide


Thông tin thuốc gốc
Chỉ định và Liều dùng
Intravenous
Reversal of neuromuscular blockade
Adult: For the reversal of effects of nondepolarising neuromuscular blocking agents: 0.1-0.25 mg/kg (approx 10-20 mg) via IV inj. Atropine or glycopyrronium bromide IV must be given immediately before or simultaneously with pyridostigmine bromide.

Oral
Paralytic ileus, Postoperative urinary retention
Adult: As conventional tab: 60-240 mg daily. Dosing frequency may vary according to patient's needs.
Child: As conventional tab: 15-60 mg daily. Dosing frequency may vary according to patient's needs.

Oral
Myasthenia gravis
Adult: Dosage and dosing frequency must be individualised, considering severity of symptoms and patient's tolerability. As conventional tab or oral solution: Usual total daily dose: 300-1,200 mg; higher doses may be needed by some patients. Doses are divided throughout the day, given when maximum strength is needed (e.g. on rising and before mealtimes). Total daily doses higher than 450 mg may be associated with increased side effects. As extended-release tab: 180-540 mg once daily or bid (with at least 6 hours interval between doses). Recommendations may vary among individual products and between countries (refer to specific product guidelines).
Child: As conventional tab or oral solution: <6 years Initially, 30 mg; 6-12 years Initially, 60 mg. May increase doses in increments of 15-30 mg daily until a satisfactory response is achieved. Usual total daily dose: 30-360 mg. Dosage recommendations may vary among individual products and between countries (refer to specific product guidelines).
Suy thận
Lower initial doses may be required; titrate to desired effect.
Cách dùng
May be taken with or without food. ER tab: Swallow whole & do not break/crush/chew. Oral soln: For patients w/ difficulty swallowing, may be administered via feeding tubes. Consult product literature for specific recommendations.
Chống chỉ định
Mechanical gastrointestinal or urinary obstruction.
Thận trọng
Patient with bradycardia or cardiac arrhythmia, recent coronary occlusion, hypotension, vagotonia; bronchial asthma, COPD; epilepsy or parkinsonism, hyperthyroidism, peptic ulcer, glaucoma, bromide sensitivity. Requirement for pyridostigmine bromide may be reduced following thymectomy. Renal impairment. Neonates, children, and elderly. Pregnancy and lactation.
Tác dụng không mong muốn
Significant: Hypersensitivity reactions, cardiac effects (e.g. bradycardia, syncope, AV block), gastrointestinal effects (e.g. abdominal cramps, increased peristalsis, sialorrhoea, diarrhoea, nausea, vomiting), respiratory effects (e.g. increased bronchial secretions, bronchoconstriction).
Eye disorders: Miosis, increased lacrimation, accommodation disorders (e.g. blurred vision).
Musculoskeletal and connective tissue disorders: Fasciculation, muscle cramps, muscle hypotonia, increased muscle weakness.
Nervous system disorders: Tremors.
Renal and urinary disorders: Urinary urgency.
Skin and subcutaneous tissue disorders: Rash, hyperhidrosis.
Vascular disorders: Hypotension.
IM/IV/Parenteral/PO: C
Thông tin tư vấn bệnh nhân
This drug may impair visual acuity and consequently affect the ability to react, if affected, do not drive or operate machinery.
Chỉ số theo dõi
Monitor blood pressure and heart rate and obtain ECG, especially with IV use. Assess for signs and symptoms of cholinergic reactions (e.g. nausea, vomiting, diarrhoea, increased salivation), particularly when administered via IV.
Quá liều
Symptoms: Cholinergic crisis manifested as nausea, vomiting, diarrhoea, abdominal cramps, increased peristalsis, excessive salivation, sweating, increased bronchial secretions, miosis, lacrimation, blurred vision, bradycardia or tachycardia, bronchospasm, cardiospasm, hypotension, incoordination, muscle cramps, weakness, fasciculation, and paralysis. CV and respiratory failure may also occur. Agitation, restlessness, confusion, visual hallucinations, and paranoid delusions may occur at extremely high doses. Management: Maintain an adequate airway. If respiration is severely depressed, artificial ventilation must be initiated. Administer 1-2 mg of atropine via IV to control muscarinic effects, may repeat dose every 5-30 minutes as needed.
Tương tác
Requirement for pyridostigmine bromide may be reduced with corticosteroids and immunosuppressant drugs. Antagonised muscarinic effect with atropine and hyoscine. Pyridostigmine bromide antagonises the effect of nondepolarising muscle relaxants (e.g. pancuronium bromide, vecuronium bromide). May prolong the effect of depolarising muscle relaxants (e.g. suxamethonium). May enhance the bradycardic effect of β-blockers. May cause or exacerbate night vision problems with antiglaucoma agents.
Tác dụng
Description:
Mechanism of Action: Pyridostigmine bromide, a quaternary ammonium compound, is a reversible cholinesterase inhibitor. It inhibits the destruction of acetylcholine by acetylcholinesterase, thereby facilitating transmission of nerve impulses across the neuromuscular junction.
Onset: Myasthenia gravis: Within 30 minutes (oral [conventional tab]). Reversal of nondepolarising neuromuscular blocking agents: Approx 6 minutes (IV).
Duration: 3-6 hours (oral [conventional tab]); 2-3 hours (IV).
Pharmacokinetics:
Absorption: Poorly absorbed from the gastrointestinal tract. Bioavailability: 10-20%. Time to peak plasma concentration: 1-2 hours (oral).
Distribution: Poor penetration into the CNS. Crosses the placenta and enters breast milk. Volume of distribution: 0.53-1.76 L/kg.
Metabolism: Metabolised in the liver and undergoes hydrolysis by cholinesterases to 3-hydroxy-N-methylpyridinium (main metabolite) and other unidentified metabolites.
Excretion: Via urine (approx 80-90% as unchanged drug). Elimination half-life: 1-2 hours (oral [conventional tab]); approx 1.5 hours (IV).
Đặc tính

Chemical Structure Image
Pyridostigmine bromide

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 7550, Pyridostigmine Bromide. https://pubchem.ncbi.nlm.nih.gov/compound/Pyridostigmine-Bromide. Accessed Feb. 23, 2024.

Bảo quản
Store below 30°C. Protect from light and moisture. Storage recommendations may vary among individual products. Refer to specific product guidelines.
Phân loại MIMS
Thuốc giải độc & khử độc / Thuốc trị rối loạn thần kinh-cơ / Các thuốc tiết niệu-sinh dục khác
Phân loại ATC
N07AA02 - pyridostigmine ; Belongs to the class of anticholinesterase. Used as parasympathomimetics.
Tài liệu tham khảo
Anon. Pyridostigmine (Pediatric and Neonatal Lexi-Drugs). Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 12/01/2024.

Anon. Pyridostigmine. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 19/10/2023.

Anon. Pyridostigmine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 12/01/2024.

Buckingham R (ed). Pyridostigmine Bromide. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/10/2023.

iNova Pharmaceuticals (New Zealand) Limited. Mestinon 60 mg Tablets data sheet 10 May 2022. Medsafe. http://www.medsafe.govt.nz. Accessed 03/10/2023.

Joint Formulary Committee. Pyridostigmine Bromide. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 03/10/2023.

Mestinon 60 mg Tablets (Mylan Products Ltd). MHRA. https://products.mhra.gov.uk. Accessed 03/10/2023.

Mestinon Dragees 60 mg; Mestinon Tablet 10 mg (A. Menarini Singapore Pte. Ltd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 03/10/2023.

Mestinon Solution, Tablet, and Tablet, Extended Release (Bausch Health US, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 03/10/2023.

Paediatric Formulary Committee. Pyridostigmine Bromide. BNF for Children [online]. London. BMJ Group, Pharmaceutical Press, and RCPCH Publications. https://www.medicinescomplete.com. Accessed 12/01/2024.

Pyridostigmine Bromide 12 mg/mL Oral Solution (Horizon Pharmaceuticals Limited). MHRA. https://products.mhra.gov.uk. Accessed 03/10/2023.

Pyridostigmine Bromide Solution (Athem LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 03/10/2023.

Pyridostigmine Bromide Tablet (Amneal Pharmaceuticals of New York LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 12/01/2024.

Pyridostigmine Bromide Tablet, Extended Release (Alvogen, Inc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 12/01/2024.

Pyridostigmine. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com. Accessed 12/01/2024.

Pyrimine Tablet 60 mg (Prestige Pharma Sdn Bhd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 03/10/2023.

Regonol Injection, Solution (Sandoz Inc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 03/10/2023.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Pyridostigmine bromide từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2024 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
  • Basori
  • Dostrep
  • MesHanon
  • Mestinon
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in